Dave Williamson
XMFGreenwave4
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Recent Articles by Dave Williamson

Apr 6, 2017
by Dave Williamson
The Worst Health Care Stocks of 2011

Apr 6, 2017
by Dave Williamson
Exelixis: 1 to Watch for 2012

Apr 6, 2017
by Dave Williamson
2012 Newest Biotech Trend

Apr 6, 2017
by Dave Williamson
The Worst Health-Care Stocks of 2011

Apr 6, 2017
by Dave Williamson
This Biotech Is No One-Hit Wonder

Apr 6, 2017
by Dave Williamson
1 Dividend to Buy, 1 Dividend to Sell

Apr 6, 2017
by Dave Williamson
Health Care's Worst Stocks 2011: Dendreon

Apr 6, 2017
by Dave Williamson
The Dow's 3 Biggest Losers

Apr 6, 2017
by Dave Williamson
1 Dividend to Buy, 1 Dividend to Sell

Apr 6, 2017
by Dave Williamson
The 2012 Dogs of the Dow

Apr 6, 2017
by Dave Williamson
Health Care's Hottest Duo

Apr 6, 2017
by Dave Williamson
4 Biotechs Dominating the Week

Apr 6, 2017
by Dave Williamson
Big Changes Coming to Big Pharma

Apr 6, 2017
by Dave Williamson
Cell Therapeutics' Wild Week
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.